World's Best Scientists 2026 revealed!
Douglas J. Schwartzentruber

Douglas J. Schwartzentruber

D-Index & Metrics

Immunology

D-Index
54
Citations
28778
World Ranking
3833
National Ranking
1756

Best Publications

  • Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes

    Mark E. Dudley;John R. Wunderlich;Paul F. Robbins;James C. Yang

  • A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer

    James C. Yang;Leah Haworth;Richard M. Sherry;Patrick Hwu

  • Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.

    S A Rosenberg;B S Packard;P M Aebersold;D Solomon

  • Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

    Steven A. Rosenberg;James C. Yang;Douglas J. Schwartzentruber;Patrick Hwu

  • Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

    Giao Q. Phan;James C. Yang;Richard M. Sherry;Patrick Hwu

  • Treatment of Patients With Metastatic Melanoma With Autologous Tumor-Infiltrating Lymphocytes and Interleukin 2

    Steven A. Rosenberg;John R. Yannelli;James C. Yang;Suzanne L. Topalian

  • gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.

    Douglas J. Schwartzentruber;David H. Lawson;Jon M. Richards;Robert M. Conry

  • Randomized Study of High-Dose and Low-Dose Interleukin-2 in Patients With Metastatic Renal Cancer

    James C. Yang;Richard M. Sherry;Seth M. Steinberg;Suzanne L. Topalian

  • Prospective Randomized Trial of High-Dose Interleukin-2 Alone or in Conjunction With Lymphokine-Activated Killer Cells for the Treatment of Patients With Advanced Cancer

    Steven A. Rosenberg;Michael T. Lotze;James C. Yang;Suzanne L. Topalian

  • Tumor Progression Can Occur despite the Induction of Very High Levels of Self/Tumor Antigen-Specific CD8+ T Cells in Patients with Melanoma

    Steven A. Rosenberg;Richard M. Sherry;Kathleen E. Morton;William J. Scharfman;William J. Scharfman

  • Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma

    Mark E. Dudley;John Wunderlich;Michael I. Nishimura;David Yu

  • A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma.

    Mark E. Dudley;John R. Wunderlich;James C. Yang;Patrick Hwu

  • Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1.

    Sharilyn K. Stanley;Mario A. Ostrowski;Jesse S. Justement;Kira Gantt

  • Prospective Randomized Trial of the Treatment of Patients With Metastatic Melanoma Using Chemotherapy With Cisplatin, Dacarbazine, and Tamoxifen Alone or in Combination With Interleukin-2 and Interferon Alfa-2b

    Steven A. Rosenberg;James C. Yang;Douglas J. Schwartzentruber;Patrick Hwu

  • Immunizing Patients With Metastatic Melanoma Using Recombinant Adenoviruses Encoding MART-1 or gp100 Melanoma Antigens

    Steven A. Rosenberg;Yifan Zhai;James C. Yang;Douglas J. Schwartzentruber

  • Identification of dynamically distinct subpopulations of T lymphocytes that are differentially affected by HIV.

    Joseph A. Kovacs;Richard A. Lempicki;Igor A. Sidorov;Joseph W. Adelsberger

  • A Breast and Melanoma-Shared Tumor Antigen: T Cell Responses to Antigenic Peptides Translated from Different Open Reading Frames

    Rong Fu Wang;Samuel L. Johnston;Gang Zeng;Suzanne L. Topalian

  • High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014

    Janice P Dutcher;Douglas J Schwartzentruber;Howard L Kaufman;Sanjiv S Agarwala

  • Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report.

    J C Yang;S L Topalian;D Parkinson;D J Schwartzentruber

  • In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2.

    Douglas J. Schwartzentruber;Sophia S. Hom;Roya Dadmarz;Donald E. White

Frequent Co-Authors

Steven A. Rosenberg
Steven A. Rosenberg National Institutes of Health
Suzanne L. Topalian
Suzanne L. Topalian Johns Hopkins University
James Chih-Hsin Yang
James Chih-Hsin Yang National Taiwan University
Patrick Hwu
Patrick Hwu The University of Texas MD Anderson Cancer Center
Seth M. Steinberg
Seth M. Steinberg National Institutes of Health
Nicholas P. Restifo
Nicholas P. Restifo National Institutes of Health
Francesco M. Marincola
Francesco M. Marincola National Institutes of Health
John R. Wunderlich
John R. Wunderlich National Institutes of Health
Howard L. Kaufman
Howard L. Kaufman Harvard University
Leslie G. Biesecker
Leslie G. Biesecker National Institutes of Health

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Best Scientists Citing Douglas J. Schwartzentruber

Recently Published Articles